Skip to content

Comparison of Uterine Repair Methods for Cesarean Delivery

Randomized Controlled Trial of Uterine Exteriorization Versus in Situ Repair for Elective Cesarean Delivery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02587013
Enrollment
180
Registered
2015-10-27
Start date
2015-11-30
Completion date
2018-07-31
Last updated
2018-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complications; Cesarean Section

Brief summary

This study is designed to compare the exteriorization of the uterus versus the in situ repair for closure of the hysterotomy incision with a completely standardized anesthetic protocol.

Detailed description

Two well-known uterine repair techniques are described; the uterus can be repaired in situ within the peritoneal cavity (intraabdominal) or exteriorized temporarily from the abdomen for the closure of the hysterotomy incision (extraabdominal). 3 meta-analysis on the topic were unable to demonstrate the superiority of one technique regarding maternal morbidities. However, there is a paucity of studies with a standardized anesthetic protocol evaluating these outcomes. This study will evaluate the impact of the uterine repair technique on different maternal morbidities; focusing on intra-operative nausea and vomiting under a standardized anesthetic protocol.

Interventions

PROCEDUREType A of uterine repair: In situ

The uterine incision is closed with the uterus within the abdominal cavity

PROCEDUREType B of uterine repair: Exteriorization

The uterine incision is repaired with the exteriorization of the uterus

Sponsors

Maisonneuve-Rosemont Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Elective cesarean delivery * Term gestation, 37 weeks or more * Healthy parturients (ASA 1 and 2) * Spinal anesthesia

Exclusion criteria

* Conditions at risk of uterine atony and/or postpartum hemorrhage (multiple gestation, placenta accrete / previa, pre-eclampsia / eclampsia, uterine leiomyomata, polyhydramnios) * Morbid obesity (BMI \> 35 kg / m2) at delivery * Coagulopathy * Active labor * Cardiomyopathy * Emergency cesarean section * Refusal/Inability to consent * Language other than English or French

Design outcomes

Primary

MeasureTime frameDescription
Incidence of intraoperative nausea and vomitingIntraoperativeIncidence of intraoperative nausea and vomiting using a scale of 0 to 3; 0 being no nausea, 1 being light nausea, 2 being severe nausea, and 3 being nausea accompanied with vomiting and / or retching. The patients will be questioned at 5 pre-determined time points during the cesarean delivery.

Secondary

MeasureTime frameDescription
Pelvic irrigationIntraoperativeTo determine if the patient had pelvic irrigation, yes or no
Length of surgeryIntraoperative
Estimated blood lossIntraoperativeMeasuring suction canisters and wet sponges
Reduction in hemoglobinWithin 24 hours of surgeryDifference between preoperative and postoperative hemoglobin within 24 hours of surgery
Incidence of hypotensionIntraoperativeHypotensive episodes, defined as a difference of more than 20% of the baseline mean arterial pressure, despite a phenylephrine infusion
Time to return of bowel functionUp to 2 weeksThe return of bowel function will be assessed by listening to each of the four abdominal quadrants for intestinal peristalsis with a stethoscope twice a day and by assessing the time of the first gas or bowel movement. The first occurrence of any of these events will determine the return of intestinal transit.
Length of hospital stay after the cesarean deliveryThrough study completion on average of 1 year
Incidence of tachycardiaIntraoperativeTachycardia, defined as a heart rate above 100 beats per minute
Incidence of endometritisThrough study completion; on average of 1 year

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 18, 2026